|Bid||81.00 x 1100|
|Ask||88.75 x 1400|
|Day's Range||84.01 - 85.25|
|52 Week Range||66.20 - 125.61|
|Beta (5Y Monthly)||0.69|
|PE Ratio (TTM)||14.95|
|Earnings Date||Jul 28, 2021 - Aug 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||119.69|
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, July 29, 2021 to report its second quarter 2021 financial results and provide a corporate update.
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on July 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 25,762 shares of its common stock and an aggregate of 12,880 restricted stock units (RSUs) to 12 new employees under Blueprint Medicines' 2020 Inducement Plan.